{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:58:19Z","timestamp":1761919099021},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2008,5,14]],"date-time":"2008-05-14T00:00:00Z","timestamp":1210723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Kinetics of hepatitis C virus (HCV) during pegylated interferon (PEG\u2010IFN) and early monitoring of viral decline were recently described to predict treatment outcomes and in turn reduce the course of treatment, adverse effects and cost. However, there is limited (if any) information on the viral dynamics of HCV\u20104. Our aim is to follow the HCV\u2010RNA kinetics during PEG\u2010IFN alpha 2a and ribavirin therapy and the best time for predicting sustained viral response (SVR) in genotype\u20104 patients. Serum HCV\u2010RNA levels before initial dosing (baseline level) and at 24\u2003h, week 1, week 4, week 12, week 24, week 48 and week 72 were assessed in 84 HCV genotype\u20104 patients treated weekly by PEG\u2010IFN alpha 2a and daily ribavirin. At the end of treatment, out of the 84 treated patients, 19 (22.6%) were non\u2010responders while 65 (77%) showed end\u2010of\u2010treatment response (ETR). However, 8 patients relapsed (9.5%), thus the SVR was observed in 57 patients (67.9%). Younger patients were more likely to attain SVR, where the odds of SVR increased by a factor of 0.94 for each year increase in age (95% CI: 0.90\u20130.99, <jats:italic>P<\/jats:italic>\u2003=\u20030.019). Although a significant negative correlation between stage of fibrosis and rate of viral decline at weeks 1 and 4 (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.005 and 0.001, respectively) was seen, neither fibrosis stage (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2003=\u20033.4882, <jats:italic>P<\/jats:italic>\u2003&gt;\u20030.1) nor grade of inflammation (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>\u2003=\u20030.0057, <jats:italic>P<\/jats:italic>\u2003&gt;\u20030.1) significantly predicted response to treatment. Non\u2010responders had no or only a limited decline at week 1 and week 4, whereas sustained virological responders had a significant decline at both week 1 and week 4. Area under the (receiver operating characteristic) curve (AUC) revealed that week 12 is better than any other time point in predicting the SVR (AUC\u2003=\u20030.97; 95% CI: 0.94\u20131.01), (sensitivity 98.3%; 95% CI: 90.7\u201399.9), (specificity 88.5%; 95% CI: 71.0\u201396.0), positive predictive value of 94.9% and negative predictive value of 95.8%. A drop of more than 1.17 log viral load at week 1 and viral clearance or decline &gt;3\u2003log were considered as the earliest predictors of SVR. In genotype\u20104 patients, while failure to achieve an EVR at week 12 predicts non\u2010response, an RVR at week1 and week 4 98% guaranteed SVR. These findings further re\u2010enforce the value of week 12 in the course of IFN treatment. Genotype\u20104 patients who show significant viral clearance (&gt;1.17log viral load) by the first week of treatment and viral clearance &gt;3log by week 4 are expected to show SVR and should therefore be assigned to a shorter drug regimen lasting for 24\u2003weeks. Those unfortunate cases who do not achieve viral clearance by week 1 or week 4 should not be deprived from the treatment but rather given more time till week 12 before being classified as non\u2010responders.<\/jats:p>","DOI":"10.1111\/j.1365-2893.2008.00988.x","type":"journal-article","created":{"date-parts":[[2008,5,15]],"date-time":"2008-05-15T02:34:22Z","timestamp":1210818862000},"page":"591-599","source":"Crossref","is-referenced-by-count":9,"title":["Viral kinetic of HCV genotype\u20104 during pegylated interferon alpha 2a: ribavirin therapy"],"prefix":"10.1111","volume":"15","author":[{"given":"M. F.","family":"Derbala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. Z.","family":"El Dweik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. R.","family":"Al Kaabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. D.","family":"Al\u2010Marri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Pasic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. B.","family":"Bener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. M.","family":"Shebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Amer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. T.","family":"Butt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Yakoob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Al Mohanadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Al Khinji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,8]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840360703"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh015"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/315661"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20414"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50217"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840360719"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50218"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401118"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.148.3.6878708"},{"key":"e_1_2_8_12_2","article-title":"The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65\u2003year","volume":"31","author":"Antonucci G","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00604.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i35.5692"},{"key":"e_1_2_8_15_2","first-page":"199","article-title":"Portal blood velocity and portal blood flow in patients with chronic viral hepatitis: relation to histological liver fibrosis","volume":"43","author":"Koda M","year":"1996","journal-title":"Hepatogastroenterology"},{"issue":"1","key":"e_1_2_8_16_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/135965350601100107","article-title":"Hepatic interferon receptor mRNA expression: clinical relevance and its relationship with effectiveness of interferon plus ribavirin therapy in patients with genotype 1b hepatitis C virus infection","volume":"11","author":"Lee CM","year":"2006","journal-title":"Antivir Ther"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6346(00)00076-0"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.4.1902-1909.2005"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i23.3722"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.03009.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2002.00377.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20232"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00621.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.24006"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00710.x"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-5926-4-9"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21917"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.04904.x"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50218"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2893.2008.00988.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2893.2008.00988.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:58:23Z","timestamp":1696985903000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2893.2008.00988.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1111\/j.1365-2893.2008.00988.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2893.2008.00988.x","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,8]]}}}